Use of high flow nasal cannula (HFNC) to deliver aerosolized medications to children has gained considerable interest. However, data on continuous albuterol delivery (CAD) via HFNC are lacking. This study quantified CAD via HFNC/vibrating mesh nebulizer (VMN) and large-volume jet nebulizer (LVN) with face mask (FM) in a pediatric model. Aerosol delivery with two HFNC cannula designs were also compared.
A pediatric manikin was connected to a lung simulator (Vt=150 ml, RR=28 breaths/min, I:E 1:2.4) via collecting filter at the carina. XL Pediatric and SML Adult HFNC designs were tested to determine optimal cannula design for CAD. VMN was placed prior to humidifier (37˚C), albuterol (5 mg/ml) was nebulized at 3, 6, & 12 L/min (n=3). To compare HFNC/VMN with LVN and FM, albuterol (15 mg/hr) was aerosolized for 3 hours/device (n=3). LVN was connected to FM and filled with 9 ml of albuterol (5 mg/ml) and 66 ml of normal saline to deliver 25 ml/hour at 13 L/min. VMN was connected to the infusion pump to deliver 7.5 ml/hr of albuterol (2 mg/ml). Drug eluted from filters was assayed with UV spectrophotometry (276 nm).
Optimal aerosol delivery occurred at 3 L/min (12.6% ± 0.5%) with SML Adult HFNC (P = .04). When used for CAD, inhaled drug delivery with HFNC/VMN (2.2 mg/hr ± 0.1, 14.8% ± 0.7%) was significantly greater than LVN and FM (0.48 ± 0.09 mg/hr, 3.2% ± 0.6%) (P = .001).
Administration of CAD via HFNC/VMN led to a greater than 4-fold increase in drug delivery compared to LVN with FM. Optimal aerosol delivery occurred at 3 L/min with SML Adult HFNC. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.